Latest filing published 30 Jul 2026 for Karyopharm Therapeutics Inc., €1,179.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Stuart Poulton (senior executive) discloses dealings in Karyopharm Therapeutics Inc. to SEC (Form 4). Between 15 February 2023 and 28 July 2026, the trades on record add up to 25 filings.
Sales make up the whole of the open-market record (16 sales, €129k). The rest of the record consists of 9 share grants. Since January 2026: no purchases and 3 sales on the market.
Most recently, on 30 July 2026, the filings show an open-market sale worth €1,179 in Karyopharm Therapeutics Inc. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
19 of 19 declarations